Ironwood Pharmaceuticals, Inc. (IRWD)
$3.76-1.57%Close
SELLRECOVERY · day 3
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $619M
- Beta
- 0.22
- P/E (TTM)
- 4.56
- Short % float
- 9.81%
- Days to cover
- 6.2
- SI change
- -16.9%
- 1W
- +3.01%
- 1M
- -7.84%
- vs SPY 1W
- +2.59%
- vs SPY 1M
- -9.90%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 9
- VALUE
- 19
- GROWTH
- 69
- GARP
- 4
- TYPE
- Value / Recovery
Composite of Value · Growth · GARP
ROIC-34.4%
REV YoY-
ROE-57.4%
EPS YoY-
ROA45.5%
GROSS100
OP61
NET33
[VALUATION]
P/E TTM4.56
P/E FWD3.12
SECTOR PE20.54
INDUSTRY PE19.83
P/B-3.71
P/FCF-
EV/EBITDA3.79
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO6.06
ND/EBITDA-
BETA0.22
Company news
FAQ
- What is LOPJLB’s current signal on IRWD?
- LOPJLB’s latest quantitative signal on Ironwood Pharmaceuticals, Inc. (IRWD) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is IRWD in?
- Ironwood Pharmaceuticals, Inc. (IRWD) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Ironwood Pharmaceuticals, Inc. (IRWD) do?
- Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or…